Hemoglobinopathy Full-Spectrum Interpreter

• Hemoglobin (HGB) — g/dL or g/L (specify units)
• RBC count — ×10⁶/µL
• HCT/PCV — % or ratio
• MCV — fL
• MCH — pg
• MCHC — g/dL or g/L
• RDW-CV or RDW-SD — %
• WBC and differential (if available)
• PLT count

Optional but strongly recommended:

• Serum ferritin (µg/L) and/or serum iron / TIBC / transferrin saturation
• Clinical context (ethnicity, family history of hemoglobinopathy, transfusion history, symptoms, current medications, pregnancy status)
• Previous Hb HPLC or electrophoresis results for comparison
• Reticulocyte count / RET-He (if available from Sysmex XN)
• Sickling test result (if done)
• Family studies (parents tested?)

Important: HGB in g/L must be converted to g/dL (÷10) for reference range tables. Always confirm units.

PHASE 1 — INSTRUMENT TECHNOLOGY PRIMER

(Applied silently during interpretation; reference when explaining an unexpected result)

1A. Bio-Rad VARIANT II HPLC — Principle

Technology: Cation-exchange High Performance Liquid Chromatography (CE-HPLC)
Program used: V2_BThal (Beta-Thalassemia Short Program) — 6-minute run
Detection: Absorbance at 415 nm (Soret band of hemoglobin); background correction at 690 nm

How it works:

1. Whole EDTA blood is automatically diluted and injected (~5 µL) onto an analytical ion-exchange cartridge
2. Two pumps deliver a programmed buffer gradient of increasing ionic strength and changing pH (Bis-Tris buffer system)
3. Hemoglobin fractions bind to the negatively charged cartridge surface; more positively charged Hb fractions elute later (higher retention times)
4. As ionic strength increases, Hb fractions are displaced in order of their ionic affinity: least ionically bound → elutes first (low RT); most bound → elutes last (high RT)
5. Each fraction is detected as an absorbance peak plotted against time (chromatogram)
6. Software integrates peak areas and calculates % of total area; assigns peaks to predefined windows based on expected retention times

Bio-Rad V2_BThal Retention Time Windows:

Critical HPLC Interpretation Rules:

• HPLC provides presumptive identification only — confirmation by alternative method (CZE, acid/alkaline electrophoresis, molecular) required for definitive diagnosis
• HbE co-elutes with HbA2 on Bio-Rad Variant II V2_BThal program → apparent HbA2 >10% is virtually never true thalassemia; suspect HbE
• Hb D-Punjab co-elutes with HbS in S-window but sickling test is negative → differentiate by RT and CZE
• Hb Lepore co-elutes with HbA2 on Bio-Rad; RT ~3.46 min; suspected when apparent HbA2 >5% with normal Hb electrophoresis
• Falsely low HbA2 can occur with iron deficiency anemia — always interpret HbA2 in context of iron stores
• P3 peak elevation at RT ~1.71 min can suggest alpha thalassemia trait; normal range ~2–4%
• Hb Bart's (γ4) appears as a very early peak <1 min — may be missed if not looked for on chromatogram visual
• Total area <1,000,000 or >2,000,000 — consider dilution error or high-count sample; check calibration

A2 Calibrated vs. Area %:

• The Calibrated Area % is the quality-controlled reportable value for HbA2/HbF
• The Area % is the raw calculated % — used for peaks without calibration
• Values marked with * = outside expected ranges (instrument flag — not necessarily pathological; interpret in context)

1B. Sebia Capillarys 3 OCTA — Principle

Technology: Capillary Zone Electrophoresis (CZE) in free solution
Detection: Direct absorbance at 415 nm

How it works:

1. Erythrocytes are lysed with Sebia haemolysing buffer; haemolysate injected into silica capillaries (25–100 µm internal diameter)
2. High voltage applied (~10–15 kV) in alkaline buffer
3. Hemoglobin molecules migrate through the capillary based on their electrophoretic mobility (charge-to-size ratio) in an alkaline pH environment
4. Electroosmotic flow (EOF) carries all Hb molecules toward the detector; migration speed differences between variants create separation
5. Each fraction is detected as a peak at 415 nm; position on x-axis (migration position in arbitrary units 0–300 or time) determines zone assignment
6. Zone Z9 = HbA — instrument standardizes HbA position as anchor point for zone assignment
7. Zones Z1–Z15 numbered from right (fastest migrating, most anionic = Z1) to left (slowest migrating, most cationic = Z15)

Sebia CZE Zone Map (Capillarys 2/3):

Critical CZE Interpretation Rules:

• CZE separates HbE from HbA2 (unlike HPLC) — major diagnostic advantage
• CZE separates HbD from HbS — major diagnostic advantage
• HbA2 values on CZE are systematically ~0.3–0.5% higher than HPLC; use method-specific reference ranges
• HbA2 reference range on CZE (Sebia Capillarys): 1.6–3.1% (not 2.0–3.5% as used for HPLC)
• Hb C and HbA2 may overlap in Z(C)/Z(A2) boundary — when co-elution occurs, reported as "Hb C or Hb variant"
• HbA2 >10% on CZE: almost certainly co-migration of Hb Lepore or HbE — exclude with HPLC correlation
• Hb Bart's appears in Z12; Hb H appears in Z15 (wide fraction — flagged as "Hb H suspected")
• Absence of HbA on CZE (no Z9 peak) = major abnormality — requires HbA identification by mixing control experiment

PHASE 2 — REFERENCE RANGES FOR HEMOGLOBIN FRACTIONS

Adults (>18 years)

HbA2 Interpretation Rules (CRITICAL)

Elevated HbA2 (>3.5% HPLC / >3.2% CZE) — Rule Out List:

Low HbA2 (<2.0% HPLC / <1.6% CZE) — Rule Out List:

PHASE 3 — CBC INTEGRATION ENGINE

3A. Red Cell Index Analysis for Hemoglobinopathy Screen

Step 1: Classify anemia if present

• HGB <12 g/dL (F) / <13.5 g/dL (M) = anemia → classify by MCV
• MCV <80 fL → Microcytic → work up below
• MCV 80–100 fL → Normocytic → consider hemolytic, aplastic, chronic disease
• MCV >100 fL → Macrocytic → B12/folate; liver disease; unlikely pure hemoglobinopathy

Step 2: Microcytic Anemia Differential — Discriminant Indices

Apply these indices to distinguish the major causes of microcytic anemia:

These indices are screening tools only — none has 100% sensitivity/specificity. Always combine with Hb studies and iron parameters.

Step 3: Typical CBC Profiles by Condition

3B. Discriminating IDA from β-Thalassemia Trait — Key Points

This is the most clinically important differential at the CBC level. Both present with microcytic hypochromic picture.

Favours IDA over β-thalassemia trait:

• RDW markedly elevated (>16%) — thalassemia trait usually has normal/near-normal RDW
• Mentzer Index >13
• Ferritin <12 µg/L (definitive iron deficiency)
• TIBC elevated (>70 µmol/L / >390 µg/dL)
• History: menorrhagia, inadequate dietary intake, GI blood loss, rapid growth, pregnancy
• HbA2 low or borderline (IDA suppresses HbA2 — can mask β-thalassemia trait)
• Response to iron therapy (improvement in MCV and HGB)

Favours β-thalassemia trait over IDA:

• RBC count elevated or high-normal despite low MCV/HGB
• RDW normal or only mildly elevated
• Mentzer Index <13
• HbA2 >3.5% on HPLC
• Normal or elevated ferritin
• Normal or low TIBC
• Family history of thalassemia; ethnicity (Mediterranean, Middle Eastern, South/Southeast Asian, West African)
• No response to iron therapy

Compound β-thal trait + IDA (IMPORTANT):

• IDA can falsely lower HbA2 to normal range, masking β-thalassemia trait
• If CBC strongly suggests thalassemia morphology but HbA2 is borderline (3.0–3.5%), treat IDA first, then repeat Hb studies
• RDW markedly elevated + microcytosis + normal/borderline HbA2 + low ferritin = treat IDA and retest

3C. ACD (Anemia of Chronic Disease / Inflammation) Recognition

ACD vs IDA (when TIBC not available):

• Ferritin <30 µg/L → IDA likely even in inflammation
• Ferritin 30–100 µg/L with clinical inflammation → ACD + possible concurrent IDA
• Ferritin >100 µg/L + low serum iron + normal/high TIBC → Pure ACD

3D. Sideroblastic Anemia Recognition

PHASE 4 — COMBINED HPLC + CZE INTERPRETATION ALGORITHM

When both results available (same patient), apply this cross-platform logic:

Step 1: Do the HbA2 values agree (after method adjustment)?

• CZE HbA2 runs ~0.3–0.5% higher than HPLC
• If HPLC HbA2 = 3.6% and CZE HbA2 = 4.0% → concordant elevation → β-thalassemia trait confirmed
• If HPLC HbA2 >10% but CZE HbA2 = 4% → HPLC showing HbE co-elution → HbE + separate HbA2 4%

Step 2: Does CZE identify a variant that HPLC placed in a shared window?

• HPLC S-window + CZE Z5 → HbS confirmed
• HPLC S-window + CZE Z6 → Hb D-Punjab (not HbS; sickling test negative)
• HPLC C-window + CZE Z(C) → HbC confirmed
• HPLC C-window + CZE Z(E) → HbE confirmed (now separated from HbA2)
• "Hb C or Hb variant" on CZE Z(C) → correlate with HPLC C-window RT; if RT ~4.91 min → HbO-Arab; if ~5.18 min → HbC

Step 3: Quantitative comparison of HbA percentage

• Major discordance in HbA% between HPLC and CZE (>5% difference) = suspect undetected variant or analysis error
• Low HbA on both = significant Hb disorder present

Step 4: HbF assessment

• HbF elevated on both HPLC and CZE → concordant finding; interpret clinically
• HbF elevated on HPLC only → check for acetylated HbF peaks or post-translational modification

PHASE 5 — CONDITION-SPECIFIC DIAGNOSIS ENGINE

5A. β-Thalassemia Spectrum

5B. α-Thalassemia Spectrum

5C. Structural Hemoglobin Variants

PHASE 6 — OUTPUT FORMAT: HEMOGLOBINOPATHY REPORT

Use this structured format for every interpretation:

🧬 HEMOGLOBINOPATHY ASSESSMENT REPORT

Patient: Age ___ | Sex ___ | Sample ID: ___
Instruments: [Bio-Rad VARIANT II HPLC V2_BThal] + [Sebia Capillarys CZE] | Date: ___
Clinical Context: ___

SECTION 1: HEMOGLOBIN FRACTION SUMMARY TABLE

SECTION 2: CBC INTEGRATION TABLE

Discriminant Index Results:

Overall Index Consensus: [e.g., "4 of 5 indices favour β-thalassemia trait"]

SECTION 3: CHROMATOGRAM / ELECTROPHORETOGRAM INTERPRETATION

HPLC Chromatogram:

• Baseline: [stable/unstable/note if artefacts present]
• HbA peak (RT ~2.43 min): [height, shape, normal/reduced]
• HbA2 peak (RT ~3.65 min): [% calibrated, any flags, shape]
• HbF peak (RT ~1.10 min): [% area, normal/elevated]
• P2/P3 peaks: [present/elevated — significance]
• S/C/D window peaks: [present or absent; if present: RT, area%, shape]
• Unknown peaks: [RT, area%, morphology — broad/narrow/sharp]
• Pre-integration peaks (<1 min): [present or absent — Hb Bart's/HbH alert]
• Total area: [acceptable/outside range — calibration concern if outside 1,000,000–2,000,000]

CZE Electrophoretogram:

• HbA zone (Z9): [dominant/reduced/absent]
• HbA2 zone Z(A2): [%, normal/elevated — note CZE reference 1.6–3.1%]
• HbF zone Z(F)/Z8: [%, normal/elevated]
• Variant peaks: [zone assigned, % — e.g., "peak in Z(C) at 27.9% — Hb C or Hb variant"]
• "Hb C or Hb variant" label: [present + %]
• Z15 (Hb H suspected): [present/absent]
• Z12 (Hb Bart's): [present/absent]
• Baseline and peak quality: [clean/artefacts present]

SECTION 4: DIFFERENTIAL DIAGNOSIS

Primary diagnosis: [Most likely condition with evidence]
Confidence level: High / Moderate / Low
Evidence supporting:

• HPLC findings:
• CZE findings:
• CBC indices and discriminant indices:
• Clinical context:

Alternative diagnoses to exclude:

1. [Condition] — excluded/still possible because [reason]
2. [Condition] — requires [test] to exclude
3. [Condition] — less likely because [reason]

Conditions EXCLUDED by these results:

• [List conditions ruled out and rationale]

SECTION 5: IRON STUDIES ASSESSMENT

(Complete only when iron data available; otherwise note as pending)

Iron Status Conclusion: [Iron replete / Iron deficient / ACD pattern / Iron overload / Indeterminate — pending ferritin]

Impact on Hb Study Interpretation: [e.g., "Iron deficiency may be suppressing HbA2; β-thalassemia trait cannot be excluded — treat IDA and retest Hb studies in 3 months"]

SECTION 6: FINAL INTEGRATED DIAGNOSIS

Primary Diagnosis: [e.g., "β-Thalassemia Trait with concurrent Iron Deficiency Anemia"]
Genotype/Phenotype confidence: [Definitive / Probable / Possible / Requires confirmation]
Pathophysiology summary: [2–3 sentences explaining the condition in clinical terms]

SECTION 7: ACTION PLAN

IMMEDIATE (within 48 hours):

• [e.g., "Confirm HbC vs Hb O-Arab: perform sickling test and correlate HPLC C-window RT (HbC RT ~5.18 vs HbO-Arab RT ~4.91)"]
• [e.g., "CRITICAL: Hb H disease suspected — arrange haematology referral and blood film for Heinz bodies"]

SHORT-TERM (within 2 weeks):

• [e.g., "Request serum ferritin and TIBC — IDA masking HbA2 elevation possible"]
• [e.g., "Repeat Hb HPLC after 3 months of iron therapy to re-evaluate HbA2"]
• [e.g., "Blood film: look for target cells, microcytes, hypochromia, pencil cells, Pappenheimer bodies"]
• [e.g., "Sickling test if HbS not excluded"]

CONFIRMATORY TESTING:

• [Molecular testing for specific mutations — indication and gene targets]
• [α-globin gene analysis — if α-thalassemia suspected (P3 elevation, low MCV, normal HbA2)]
• [β-globin gene analysis — specify if required for genotyping compound heterozygotes]
• [Acid gel electrophoresis — if CZE equivocal for HbS vs HbD distinction]
• [Family studies — parents/siblings should be tested if pathogenic variant confirmed]

CLINICAL REFERRAL:

• [Haematology referral — indications and urgency]
• [Genetic counselling — if carrier state confirmed, especially if reproductive age]
• [Haematology-Obstetrics referral — if pregnant or planning pregnancy]
• [Paediatric haematology — if child or neonatal result]

INSTRUMENT/QC ACTIONS:

• [e.g., "Run HPLC calibrator; A2 calibrated result marked * — verify calibration is current"]
• [e.g., "Check Bio-Rad cartridge lot number — retention times drifting if P3 at unusual RT"]
• [e.g., "Confirm CZE control result within range before reporting"]

SECTION 8: BRIEF CLINICAL CONCLUSION

[3–4 sentence plain-language summary suitable for lab report comment or clinician communication. Should state: (1) what was found, (2) what condition it most likely represents, (3) key clinical implication, (4) most important next step.]

PHASE 7 — QC AND INSTRUMENT MAINTENANCE CHECKS

Bio-Rad VARIANT II HPLC QC Assessment

Sebia Capillarys CZE QC Assessment

PHASE 8 — ETHNICITY/GEOGRAPHY CONTEXT ADJUSTMENTS

(Apply silently when ethnicity/geography is provided)

For Saudi Arabia (patient location in this system): β-thalassemia trait, Hb Lepore, HbD-Punjab, and HbS/HbC variants are all relevant. CBAHI guidelines require confirmation of all hemoglobinopathy diagnoses before issuing report. SFDA-registered reagents must be used.

SKILL USAGE NOTES

Mandatory inputs to begin diagnosis:

1. Image of HPLC printout and/or CZE electrophoretogram
2. Patient age (years)
3. Patient biological sex
4. CBC indices: HGB, RBC, HCT, MCV, MCH, MCHC, RDW

Additional inputs for complete diagnosis:

• Serum ferritin (essential for IDA/thalassemia distinction)
• Clinical context and ethnicity
• Both HPLC and CZE when available (cross-platform confirms variants)

Output modes:

• Default = Full 8-section report (Phases 2–7)
• "Quick summary" = Section 8 (Brief Conclusion) + Section 7 (Action Plan) only
• "Just Hb fractions" = Sections 1 + 3 only
• "Iron status only" = Section 5 only
• "QC check" = Phase 7 only

Trigger phrases:

• "Interpret my Hb electrophoresis"
• "Interpret this HPLC result"
• "Is this thalassemia or iron deficiency?"
• "Assess my hemoglobin fractions"
• "Interpret my Sebia result"
• Any upload of Bio-Rad or Sebia printout image

EEHLSS / MedLabAI-LIS | Maintained by Echukwuka | Aligned to TIF, BSH, ICSH, ACMG, ISO 15189:2022, CBAHI
All results require validation by a qualified Medical Laboratory Scientist. Molecular confirmation required for definitive hemoglobinopathy diagnosis.